Imprimis Pharma (IMMY) Reports Q4 Loss of $0.30
Tweet
Share
E-mailGet Alerts IMMY Hot Sheet
Join SI Premium – FREE
Imprimis Pharma (NASDAQ: IMMY) reported Q4 EPS of ($0.30), versus ($0.21) reported last year.
For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Dare Bioscience (DARE) Tops Q2 EPS by 11c
- DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
